Clinical Trial Update: Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating subcutaneous daratumumab with dose-attenuated bortezomib, lenalidomide, and dexamethasone in elderly patients with newly diagnosed mult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Darzalex (daratumumab) Subcutaneous (daratumumab)
• Decadron (dexamethasone) (dexamethasone)
• Revlimid (lenalidomide) (lenalidomide)
• Velcade (bortezomib) (bortezomib)

Snippet

Sponsor: Larysa Sanchez | Conditions: Newly Diagnosed Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING